The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa,

Formoterol Fumarate Inhalation Solution (RLD Perforomist®) had estimated annual sales of US$ 268 million in the U.S, according to IQVIA MAT September 2022.

Global pharma major Lupin Limited (Lupin) today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

Formoterol Fumarate Inhalation Solution had estimated annual sales of US$ 268 million in the U.S, according to IQVIA MAT September 2022.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.